Roflumilast, an eczema cream from Arcutis Biotherapeutics, achieved its primary endpoints.

Published Date: 22 Sep 2023

The INTEGUMENT-PED pivotal Phase 3 trial of roflumilast cream 0.05 percent, in children ages 2 to 5 years with mild to, was recently announced by Arcutis Biotherapeutics.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot